Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)
Status:
Terminated
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study was to evaluate how effective the combination of
Carboplatin, Bevacizumab (Avastin™) and, Pemetrexed (Alimta™) is in the treatment of patients
with Malignant Pleural Mesothelioma (MPM). A combination of cisplatin and pemetrexed is
considered standard for this disease and typically off protocol patients would receive
cisplatin or carboplatin and pemetrexed as standard of care.
The planned length of the study (first patient screened to last patient enrolled) was 24
months. The planned length of the entire study (enrollment period + the treatment period + a
follow-up period of at least 12 months) was 36 months.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute